Company intelligence / Profile preview

PDC*line Pharma

Ownership: Private
Employees: ~41
Development stage: Phase 2

Overview

Reported promising Phase I/II results in lung cancer (PDClung) in 2024. PDClung01, in combination with pembrolizumab, demonstrated potential to provide meaningful clinical benefit compared to standard treatment. Preparations underway for a randomized Phase II trial in lung cancer and a Phase Ib trial in colorectal cancer with neoantigens.

Therapeutic areas: Oncology
Modalities: Cell-based immunotherapytherapeutic cancer vaccines
Industry: Biotech

Drug pipeline

3 assets

PDC*lung01

2 more assets in the full pipeline.

Request access →

Partnerships

LG Chem Life Science (licensing deal for Asia)

Beyond the preview

Go deeper on PDC*line Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDC*line Pharma.

Explore the full profile